iSciencell

OPEN ACCESS

ArticleBacillus Calmette-Guerin ’s beneficial impact on
glucose metabolism: Evidence for broad based
applications
Gabriella F.
Shpilsky, Hiroyuki
Takahashi, Anna
Aristarkhova, ...,
Hui Zheng, Willem
M. Kühtreiber,
Denise L.
Faustmanfaustman@helix.mgh.harvard.
edu

Highlights
A pilot trial of BCG
vaccinations to T1D
showed reduced blood
sugars but not in LADA
Monocytes from T1D andto some degree T2D
display stimulated
glucose transport
BCG vaccinations at birthshow accelerated glucose
transport decades later
In vivo mouse models ofboth T1D and T2D
demonstrate BCGinduced blood sugar
lowering

Shpilsky et al., iScience 24,103150
October 22, 2021 ª 2021 The
Authors.
https://doi.org/10.1016/
j.isci.2021.103150

iSciencellOPEN ACCESS

ArticleBacillus Calmette-Guerin ’s beneficial
impact on glucose metabolism:
Evidence for broad based applications
Gabriella F. Shpilsky,1,5 Hiroyuki Takahashi,1,5 Anna Aristarkhova,1 Michele Weil,3 Nathan Ng,1 Kacie J. Nelson,1
Amanda Lee,1 Hui Zheng,4 Willem M. Kühtreiber,1,2 and Denise L. Faustman1,2,6,*
SUMMARY

Bacillus Calmette-Guerin (BCG) vaccinations improve glycemic control in juvenileonset Type I diabetes (T1D), an effect driven by restored sugar transport throughaerobic glycolysis. In a pilot clinical trial, T1D, but not latent autoimmune diabetes
of adults (LADA), exhibited lower blood sugars after multidose BCG. Using a
glucose transport assay, monocytes from T1D subjects showed a large stimulation index with BCG exposures; LADA subjects showed minimal BCG-induced
sugar responsiveness. Monocytes from T1D, type 2 diabetes (T2D), and non-diabetic controls (NDC) were all responsive in vitro to BCG by augmented sugar utilization. Adults with prior neonatal BCG vaccination show accelerated glucose
transport decades later. Finally, in vivo experiments with the NOD mouse(a T1D model) and obese db/db mice (a T2D model) confirm BCG’s blood-sugarlowering and accelerated glucose metabolism with sufficient dosing. Our results
suggest that BCG’s benefits for glucose metabolism may be broadly applicable toT1D and T2D, but less to LADA.
INTRODUCTION
The BCG (Bacillus Calmette-Guerin) vaccine has been in clinical use for >100 years for protection fromtuberculosis (Colditz et al., 1994). Over the last 15 years, diverse clinical trials have established that
this microbe-based vaccine has additional clinical benefits called heterologous effects, off-target effects,
or nonspecific effects. These terms indicate beneficial human clinical effects for diseases other thantuberculosis (de Bree et al., 2018; Freyne et al., 2015; Goodridge et al., 2016; Kandasamy et al., 2016;
Pollard et al., 2017; Shann, 2010; Yung, 2016). For instance, the BCG vaccine protects humans from being
infected with or dying from a range of infections, including upper respiratory tract infections, malaria,
yellow fever, among others (Aaby et al., 2006, 2011; de Castro et al., 2015; Higgins et al., 2016; HollmDelgado et al., 2014; Kjaergaard et al., 2016; Setia et al., 2006; Stanley et al., 1981; Stensballe et al.,2005). The BCG vaccine also protects, halts, or reverses established autoimmunity. BCG used in earlystage multiple sclerosis shows, after a 2-year interval, a halt in disease progression in double-blindedclinical trials (Ristori et al., 1999, 2014). Repeat BCG vaccinations in longstanding T1D lower blood sugars
in clinical trials (Faustman et al., 2012; Kühtreiber et al., 2018). Lastly, the BCG vaccine has been used
globally for the past 40 years to treat bladder cancer and, more recently, to treat lymphoma and lungcancer (Babjuk et al., 2017; Davignon et al., 1971; Morales et al., 1976; Odom et al., 1988; Salmon
et al., 2019, 2020; Usher et al., 2019).
The mechanisms behind these beneficial heterologous effects are under investigation. Abundant evidence
has established that BCG works through the innate immune system on monocytes by rapidly changing theircytokine expression. The effect may be controlled by increased histone 3 lysine 4 tri-methylation (Arts et al.,2018; Biering-Sorensen et al., 2018). These changes are referred to as trained immunity, a type of hostmicrobe interaction known to occur in plants, invertebrates, and mice. Characteristically, a change in histone methylation has been established to rapidly change cytokine expression patterns. This may be amechanism for BCG’s rather rapid protection from infectious diseases (Aaby et al., 2006, 2011; Biering-Sorensen et al., 2018; de Castro et al., 2015; Higgins et al., 2016; Hollm-Delgado et al., 2014; Kjaergaard et al.,2016; Arts et al., 2018; Setia et al., 2006; Stanley et al., 1981; Stensballe et al., 2005).

1Massachusetts General

Hospital, Immunobiology
Laboratories, Boston, MA
02129, USA
2Massachusetts General

Hospital and Harvard Medical
School, Immunobiology
Laboratories, Boston, MA
02129, USA
3Massachusetts General

Hospital, Diabetes Unit,
Boston, MA 02129, USA
4Massachusetts General

Hospital and Harvard Medical
School, Statistics
Department, Boston, MA
02129, USA
5The authors contributed

equally
6Lead contact*Correspondence:
faustman@helix.mgh.
harvard.edu
https://doi.org/10.1016/j.isci.
2021.103150

iScience 24, 103150, October 22, 2021 ª 2021 The Authors.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1ll

OPEN ACCESS

The mechanisms behind BCG’s beneficial systemic effects in humans also involve the adaptive immune
response, and these changes appear to occur at a slower rate over years. This process of adaptive immune
training can involve T cells as well as monocytes and centers on metabolic pathways that change aerobic
glycolysis. Thus, the use and rate of sugar metabolism is improved after BCG therapy (Kühtreiber et al.,2018, 2020). The BCG effects observed in human autoimmune clinical trials have a slower onset of disease
modifications (over years) but are permanent for >8 years in treated humans (Kühtreiber et al., 2018). Clinical examples of adaptive training include the reprogramming of T-regulatory (or Treg) cells by demethylation of key genes involved in their cellular activation (Kühtreiber et al., 2018). Another clinical example ofadaptive training is the systemic reprogramming of T cells and monocytes in metabolic pathways related toaerobic glycolysis, a pathway with T1D-inherent defects (Kühtreiber and Faustman, 2019). The durability
and the long-lasting effects of BCG vaccination have been also attributed to Th1/Th17 responses (Kleinnijenhuis et al., 2014).
Diabetes, a clinical form of high blood sugars, comes in several forms. Type 1 diabetes (T1D) is also
commonly known as juvenile-onset diabetes (Katsarou et al., 2017). Its onset is typically in childhood,with rapid loss of pancreas function from the T cell autoimmune attack on the insulin-secreting islets ofLangerhans. T1D requires life-long insulin therapy and is associated with serious morbidity and mortality.
The children produce autoantibodies to various islet-related proteins. Diabetes can also occur in adulthood in two different forms. Late autoimmune disease of adults (LADA), also called Type 1.5 diabetes, isassociated with an older age of onset (AOO), always greater than 21 years, with a mean age of onset of
30 years (Pieralice and Pozzilli, 2018). LADA subjects have a slower decline in pancreas function and also
become insulin dependent. The most prevalent form of diabetes is Type 2 diabetes (T2D). This form of diabetes typically occurs in adults with a mean onset age of 30–50 years and is associated with obesity andinsulin resistance. With time, T2D is treated with insulin but more commonly is treated with oral hypoglycemia agents, such as metformin. The genetics of T2D are distinct from the genetics of T1D. The ‘‘glue’’linking all three forms of diabetes is high blood sugar.
This study explores the breadth of BCG-induced sugar-lowering and accelerated glucose transport properties across all forms of diabetes and nondiabetic controls (NDCs). We start with a two-year pilot clinical
trial comparing T1D with LADA subjects for blood sugar control after multidoses of the BCG vaccine. Then,
using an in vitro assay of glucose metabolism to monitor the rate of cellular glucose uptake (2-NBDG), we
examine BCG’s effect on sugar uptake by monocytes from all forms of diabetes plus NDCs. We thenexamine the durability of this BCG effect by studying adults who received the BCG vaccine as neonates.
Lastly, we turn to murine models of T1D and T2D to determine whether BCG’s beneficial effect on sugar
metabolism is equally observed in two forms of divergent hyperglycemia. To confirm that BCG-induced
accelerated glucose transport is due to glycolysis, the inhibitor metformin is used in vitro and in vivo
(Arts et al., 2016; Kühtreiber et al., 2020).

RESULTSThis is a study of metabolic changes induced by the BCG vaccine in diabetic humans. This study, both in vivo
and in vitro, quantifies sugar metabolism (n = 391 subjects). In a pilot clinical trial of 62 adults followed up
for 2 years, the HbA1c response in T1D subjects (age of onset %21), LADA subjects (age of onset >21), anduntreated controls were evaluated (Figure 1). In in vitro studies, the 2-NBDG sugar utilization assay data
quantified the systemic effects of BCG. The magnitude of sugar metabolic changes was in cells from in vivo
BCG treatments, from in vitro BCG exposures, and in the setting of T1D, LADA, T2D, neonatal BCG vaccinations, and bladder cancer subjects (total n = 329 subjects) (Figures 2, 3, 4, 5, and S1). Diabetic mousestudies were performed to confirm similar mechanisms of BCG-induced alterations in metabolism thatlower blood sugars (n = 112 mice; Figure 6).

Patients with T1D, but not LADA, respond to BCG vaccinations by HbA1c lowering within 2
years
T1D is commonly referred to as juvenile-onset diabetes based on childhood onset. Herein we define T1D as
having an AOO % 21 years. Adults can also get T1D with older AOO, herein defined as AOO >21 years, andmarked by slower progression to total insulin dependence, some characteristics of T2D often with insulin
resistance, obesity, and slower C-peptide decline. This latter form of diabetes is called LADA. Publisheddata in a small, double-blinded placebo-controlled Phase I clinical trial showed juvenile-onset T1D was

2

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

Figure 1. In vivo BCG vaccinations decrease HbA1c in T1D but not LADA patients(A) Juvenile-onset T1D diabetic subjects were compared with LADA diabetic subjects for responsiveness to BCG vaccines
using the Tokyo strain over a 2-year period. Juvenile-onset diabetes was defined as age of onset <21 years. LADA subjects
were defined as having diabetes onset >21 years. Percent change from baseline in HbA1c of open-label T1D patients
receiving BCG treatment with an age of onset (AOO) % 21 years old (n = 6) (mean age of onset of 11 G 3 years) comparedwith a T1D reference population not receiving BCG treatment. The fall in HbA1c is a significant trend (repeated-measures
ANOVA p = 0.01; left). The trend in the LADA patients was not significant (n = 10; repeated-measures ANOVA p = 0.58;
right). Their mean age of onset was 31 G 2 years. The current chronological ages of the two adults groups were for 28 G 3years for the T1D and 45 G 4 years for LADA subjects. The duration of diabetes in the T1D group was 18 G 3 years, and theduration of diabetes in the LADA group was 19 G 2 years.
(B) Percent change from baseline in HbA1c of the current open-label T1D patients with AOO %21 years (n = 6; 11 G 3.0
years) receiving Tokyo BCG treatment is shown in red (n = 6) as compared with the previously published Phase 1 Sanofi
BCG clinical trial data with similarly early onset (11 G 5.8 years) (black, open triangle). Also shown are the Phase 1 placebogroup (open squares, and a reference population (closed squares).

responsive to repeat BCG vaccinations with lowered HbA1c values. These adults received the Sanofi BCG
strain (Kühtreiber et al., 2018).
We performed an open-label pilot clinical trial to investigate the reproducibility of these early observations
in T1D, to test if Tokyo BCG strain shows a similar HbA1c lowering trend as the earlier Sanofi BCG studies,and to see if LADA subjects are equally responsive to the BCG intervention over the same time course as

iScience 24, 103150, October 22, 2021

3

ll

OPEN ACCESS

Figure 2. Glucose transport by T1D, LADA, and NDC human monocytes(A) Example of flow cytometry showing gating and glucose uptake measured with 2-NBDG MFI analysis of nondiabetic
control (NDC) monocytes treated in vitro with BCG for 24 hours and then allowed to transport 2-NBDG (sugar) for 1 hour.
(B) LADA (red open dots) and T1D (red closed dots) monocytes differ both at baseline (left) and after the in vitro BCG
exposure (right) with respect to glucose transport. At baseline, T1D monocytes’ basal glucose transport was 7,641 G 325
and LADA monocytes’ was 6,804 G 170. After BCG, the MFI was 9,299 G 421 for T1D and 8,331 G 240 for LADA (p < 0.05
for both comparisons). At baseline LADA have insufficient glucose transport compared with augmented baselinetransport in T1D. The comparison of T1D +/ BCG and of LADA +/ BCG is both significant at p < 0.0001. The number ofsubjects: T1D n = 14; LADA n = 37.
(C) We next measured the stimulated glucose index of monocytes from subjects treated with BCG in vivo. As presented
above, T1D subjects had improved blood sugar control with BCG but LADA subjects at year 2 had no improvement intheir blood sugar control measured in the HbA1c assay. Comparison of the BCG stimulation index (stimulated glucose
uptake - baseline) from isolated monocytes from the clinical trial subjects shows increased glucose uptake and greater
accelerated uptake of glucose in T1D as compared with LADA. There was no significant difference between the BCG
stimulation index of T1D and NDC. Red closed dots represent T1D monocyte samples; black triangles represent
nondiabetic control monocytes, open red dots represent LADA monocyte samples. Student’s t-testing (unpaired, 1tailed) or a student’s t-testing (paired, 1-tailed) was represented as: p < 0.05 *; p < 0.01 **; p < 0.001 ***, p < 0.0001****. An
unpaired t test was used comparing T1D with either LADA or controls. A paired test was used comparing internal to self as
untreated monocytes to BCG treated monocytes. The number of subjects: T1D n = 24; LADA n = 12; NDC n = 16. (D)Summary depiction of how, after in vitro BCG exposure, the 2-NBDG sugar uptake assay detects measurable changes inmonocytes’ sugar transport.

T1D. T1D (AOO %21; n = 6; repeated-measures analysis of variance [ANOVA] p = 0.01) (Figure 1A, left),when treated in adulthood, showed uniform reductions in HbA1c over the two-year period as comparedwith baseline (Figure 1A, left). In contrast, LADA subjects over this two-year observation period did not
reduce their HbA1C values (n = 10; repeated measure ANOVA p = 0.58) (Figure 1A, right). An untreated
T1D reference population (n = 40) is also provided for context. Note that the data shown were normalizedby calculating % change in HbA1c from baseline. The raw data are shown in Figure S2. Our findings suggestthat T1D diabetic subjects (vs LADA) are most sensitive to BCG vaccination, are more homogeneous in their
response, have a greater magnitude response, and/or are at least are faster in their blood sugar lowering
responses with observations out to two years.

4

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

Figure 3. Neonatal BCG vaccinations show sustained and lifelong changes in glucose metabolism(A) Demographics of control subjects vaccinated with BCG at birth is presented by the country of birth, the BCG strain
used in that county, and the current age of subjects (a reflection of years since the vaccination).
(B) Glucose uptake in monocytes from nonvaccinated control subjects (n = 21, black dots) compared with neonatal BCG
vaccinated control subjects (n = 13, green dots). Data present baseline uptake of sugar by monocytes (left) compared withsugar uptake after 24 hour in vitro exposure to BCG (right).
(C) Baseline (top) and BCG-stimulated (bottom) monocyte glucose uptake of NDC patients (n = 21) compared on thesame scale as NDC subjects given neonatal BCG vaccinations (n = 13) (2-tailed, unpaired t test revealed a significant
difference at baseline and with stimulation. Both baseline sugar uptake (top, green) and BCG-stimulated sugar uptake(bottom, green) were monocyte characteristics from normal controls vaccinated at birth with BCG.
(D) Baseline (left) glucose uptake in monocytes of unvaccinated T1D patients (n = 42) following a one day incubation withor without in vitro BCG treatment (right). The sample marked in green represents a T1D individual with remarkablediabetes management and a mass found in their lungs suspicious for latent Mycobacterium tuberculosis infection.
p < 0.05 *; p < 0.01 **; p < 0.001 ***Because there are known differences in BCG strains, the current data from the Tokyo BCG strain werecompared with the Sanofi-strain-treated Phase I double-blinded clinical trial data, a data set having similar
early AOOs. We compared the change in HbA1c from the current open-label juvenile-onset T1D (n = 6)
cohort with our Phase 1 trial composed of juvenile-onset BCG-treated T1D cohort, the original reference

iScience 24, 103150, October 22, 2021

5

ll

OPEN ACCESS

Figure 4. T2D monocytes transport more sugar with exposures to BCG in culture, in many ways their glucose
uptake profile is similar to NDC(A) Untreated monocytes at baseline showing glucose uptake for NDC (n = 21), T1D (n = 42), and T2D (n = 13) subjects.
(B) Glucose uptake for monocytes from NDC, T1D, and T2D patients after in vitro treatment with BCG for 24 hrs.
(C) Comparison of glucose uptake by monocytes from NDC (n = 17) and T2D (n = 13). Overnight culture in BCG increased
glucose uptake in both NDC and T2D monocytes. p < 0.05 *; p < 0.01 **; p < 0.001 ***. Red dots represent T1D monocyte
samples; black dots represent nondiabetic control (NDC) monocytes, and blue dots represent T2D monocyte samples.

and original placebo groups T1D Population with the same number of BCG doses (Figure 1B). The data
show similar kinetics and uniformity of all adults with juvenile-onset T1D dosed with either the Sanofi or
the Tokyo BCG strain. Both strains show a drop in HbA1c levels over 2 years, indicating reproducibility.

Monocytes from T1D and NDCs but not LADA show accelerated sugar uptake to varying
degrees
We next tested the ability of a glucose transport assay, 2-NBDG (fluorescent glucose analogue,
C12H14N4O8), to corroborate the clinical trial observations. The 2-NBDG sugar uptake assay is a monitoring
tool that measures enhanced intracellular monocyte fluorescence when the labeled sugars are transported
inside the cell (Figure 2A). Monocytes were isolated from peripheral blood and cultured overnight with orwithout BCG. The cells were then harvested, washed, counted, incubated with 2-NBDG for 1 hour at 37 C,
and labeled with APC-anti-CD14 antibody. The cells were then analyzed using a BD FACSCanto II flow cytometer. The right shift in the histogram for 2-NBDG fluorescence on this log scale indicates that the uptake

6

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

Figure 5. Metformin inhibits glucose uptake in cultured NDC, T1D, and T2D human primary monocytes(A) Metformin inhibited glucose uptake (2-NBDG) in untreated NDC monocytes (n = 9, p = 0.00075).
(B) Metformin inhibited glucose uptake (2-NBDG) in NDC monocytes cultured in the presence of BCG (n = 9, p = 0.0047).
(C) Metformin inhibited glucose uptake (2-NBDG) in untreated T1D monocytes (n = 18, p = 0.0014).
(D) Metformin inhibited glucose uptake (2-NBDG) in T1D monocytes cultured in the presence of BCG. n = 18,
p = 3.11 3 10 6).
(E) Metformin inhibited glucose uptake (2-NBDG) in untreated T2D monocytes (n = 6, p = 0.014).
(F) Metformin inhibited glucose uptake (2-NBDG) in T2D monocytes cultured in the presence of BCG (n = 6, p = 0.0012).
All p values are from paired, 2-tailed student’s t test. p < 0.05 *; p < 0.01 **; p < 0.001 ***. Red dots represent T1D
monocyte samples, black dots represent nondiabetic control monocytes, and blue dots represent T2D monocyte
samples.

of 2-NBDG (labelled sugar) into the BCG-treated cells is higher than that into untreated control cells. The
outcome is quantified by median fluorescent intensity (MFI). A demographics table for the patients who
donated blood for these experiments is shown (Table S1).
At baseline (i.e., freshly isolated monocytes cultured overnight in the absence of BCG), sugar uptake
measured by the 2-NBDG assay showed that monocytes from T1D subjects had greater sugar transport
than monocytes from LADA subjects (T1D n = 14 and LADA n = 37; Figure 2B, left). When cultured overnight

iScience 24, 103150, October 22, 2021

7

ll

OPEN ACCESS

Figure 6. Mouse models of T1D and T2D support BCG therapeutic effects; in vitro glucose transport assays are
consistent(A) Kaplan Meyer survival plot for NOD mice that were untreated (CTRL n = 16), treated with BCG only (+BCG n = 11),treated with metformin only (+Met n = 15), or treated with metformin and BCG (+Met and +BCG n = 15). Metformin
treatment started at 6 weeks of age in vivo; BCG injections were administered at week 7 and week 13. Survival was
improved after treatment with BCG, but treatment with metformin alone or with a combination of metformin plus BCG
resulted in reduced animal survival due to severe hyperglycemia.
(B) Glucose uptake (2-NBDG) studies in isolated bone marrow cells from untreated, BCG-treated, or metformin-treateddiabetic NOD mice show significant differences between untreated and BCG-treated mice (p = 0.015), as well as between
BCG-treated and metformin treated mice (p = 0.011). In all cases, metformin was started at 6 weeks of age, and this wasthen followed by BCG treatment at 10 weeks. The number of mice: NOD n = 16; NOD + BCG n = 11; NOD + metforminn = 15.
(C) Change in blood sugar and BCG treatment regimen for obese db/db mice, a model of T2D. Arrows indicate BCG
treatment times. The BCG-treated mice have substantially lower blood sugars. Open symbols depict time points where
the difference between CTRL and BCG groups was significant in Student’s t testing. Number of mice: db/db + BCG n = 16;
db/db untreated n = 11.
(D) Change in body weight in the severely obese db/db mice suggests that BCG-treated mice are healthier since they
have lower body weight. Open symbols depict time points where the difference between CTRL and BCG groups was
significant in student’s t testing. The number of mice: db/db + BCG n = 16; db/db untreated n = 11.

8

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

Figure 6. Continued(E) In vivo BCG treatment of normal BALB/c mice and of diabetic db/db mice both result in increased glucose uptake
although the Balb/c mouse effect did not reach statistical significance as measured by 2-NBDG assays in bone marrowcells compared to untreated control mice. BALB/c: n = 4 + BCG and n = 4 untreated; p = 0.31; db/db: n = 10 BCG and
n = 10 untreated; p = 0.04.

in the presence of BCG, both T1D and LADA monocytes accelerated their sugar transport, but T1D monocytes were much more responsive than LADA monocytes (p = 0.03).
We next studied freshly isolated monocytes from clinical trial subjects, either T1D or LADA, for in vitro sugartransport after BCG treatment in vivo. These assays were performed two years into the human clinical trial.
The BCG stimulation index (BCG treatment in vitro minus untreated monocytes in vitro) rapidly demonstrated that a large augmented sugar transport was specific for T1D compared with LADA (n = 24, 12,
and 16 for T1D, LADA, and NDC, respectively; Figure 2C). Thus, 2-NBDG uptake correlated with the clinicalresponsiveness of BCG administered in vivo in T1D but not LADA subjects.
A summary of the 2-NBDG assay and the glucose uptake assay for measuring the labelled sugar is presented in Figure 2D.

Glucose uptake is accelerated decades after neonatal BCG vaccinations
Can accelerated sugar metabolism be observed decades after neonatal BCG vaccination? The subjects
used for this next study were adults vaccinated at birth with BCG (Figure 3A). Their newborn vaccinations
were performed in diverse countries and with various strains of BCG. The time intervals from vaccination to
our in vitro glucose uptake assay ranged from 25–83 years. The data show the impact of prior BCG vaccinations at birth on uptake of glucose compared with nonvaccinated adult subjects (NDC, n = 21 subjects;
neonatal vaccinations n = 13). The neonatal vaccinated nondiabetic subjects on average had BCG vaccination 55.3 G 4.5 years before this blood monocyte study. Remarkably, the monocytes from neonatal BCGvaccinated normal adult subjects (green dots) continued to have accelerated sugar transport both atbaseline and after in vitro BCG compared with NDC samples (Figure 3B, left, green dots compared withblack dots). The trends were statistically significant at baseline and with BCG stimulation compared with
nonvaccinated control monocytes (Figure 3B; NDC with childhood BCG vaccination n = 13 versus unvaccinated n = 21). With neonatal vaccinations in controls, the baseline monocyte glucose uptake was
9,099 G 626; the nonvaccinated control baseline glucose uptake was 7,433 G 303 (Figure 3C, top). With
monocyte culture with BCG for 24 hours, neonatal vaccinations in controls had stimulated glucose uptake
in monocytes of 10,397 G 537. The nonvaccinated control stimulated BCG glucose uptake was 8,746 G 377(Figure 3C, bottom). The findings suggest lifelong persistence of BCG’s metabolic effects.
The other clinical setting in which BCG is administered is as high-dose therapy for bladder cancer, almost
always in elderly populations. We asked, could normal subjects treated with high doses of BCG for bladdercancer also show changes in glucose metabolism, measured in vivo with HbA1c or through monocyte
glucose uptake assays in the form of 2-NBDG. High-dose BCG is administered in the bladder. Subjects
were studied months to 20 years after bladder cancer treated with BCG (Figure S1). Unlike neonatal vaccination, accelerated glucose transport by monocytes at baseline and after in vitro BCG exposures were notobserved. All these subjects were US citizens and based on medical records received the TICE BCG strain
as the bladder drug, a strain with less potency than other BCG strains. In addition, the stage of bladdercancer may also determine if the BCG from bladder erosions for the cancer will allow systemic population/spread of the administered BCG. These data were not feasible to obtain for this study.
We were fortunate to identify a T1D subject in our clinic with lung granulomas consistent with a latent formof mycobacteria infection for >30 years and T1D for 52 years. His clinical course was remarkable for having
lifelong near-perfect HbA1c control, always in the 5.5 to 6.5 range. Sampling of his monocytes revealed
augmented sugar transport, thus showing that even tuberculosis itself might be as protective as the
BCG vaccine; however this is a single case (Figure 3D, green dots).

T2D monocytes are responsive to BCG exposures in vitro
The third form of diabetes, T2D, was studied using the in vitro glucose uptake assay to determine responsiveness to BCG (Figure 4). The data show that T2D monocytes at baseline have adequate sugar transport

iScience 24, 103150, October 22, 2021

9ll

OPEN ACCESS

and also could respond in vitro to BCG exposures (n = 21 NDC, n = 42 T1D, n = 13 T2D, respectively [Figures
4A and 4B]). Further comparisons between NDC and T2D monocytes are also presented (Figure 4C). There
was no difference between NDC and T2D, either at baseline (untreated panel) or after culture with BCG(BCG-treated panel).

Metformin inhibits BCG-induced glucose uptake
Metformin is taken by many T2D patients to help control their blood sugars by increasing insulin sensitivity
and by inhibiting glucose neogenesis by the liver. Metformin is also taken by a small fraction of T1D. It istherefore important to establish whether metformin interferes with BCG with respect to glucose uptake
in T1D, as well as T2D in preparation for a potential use of BCG in T2D clinical trials. We therefore studied
the effect of metformin and BCG in vitro in human monocytes (Figure 5). Previous data suggest that metformin interferes with cytokines induced by BCG through innate immunity as well as with glycolysis pathways in innate and adaptive immunity (Arts et al., 2016; Kühtreiber et al., 2020).
Using the glucose metabolic assay, 2-NBDG, treatment with metformin in vitro inhibited 2-NBDG uptake inprimary human monocytes from all the clinical samples (NDC, T1D, and T2D). We isolated primary monocytes from NDC, T1D, and T2D subjects and cultured them overnight in the presence or absence of BCG
and metformin. The next day the cells were incubated with 2-NBDG and APC-anti-CD14 antibodies andanalyzed by flow cytometry. For all forms of diabetes, metformin reduced 2-NBDG uptake by the monocytes, irrespective of whether BCG was present (Figure 5). The number of subjects: 5A, B n = 9; 5C, D
n = 18; 5E, F n = 6. We thus conclude that in vitro metformin inhibits 2-NBDG uptake in both untreated
and BCG treated monocytes and thus may interfere with the beneficial effects of BCG treatment in vivo
for blood sugar control in diabetics. Metformin has its own benefits for blood glucose control in diabetes,
its effect is not likely additive with the effect of BCG, and it may not be possible to combine both
treatments.

Murine T1D model (NOD mouse) responds to BCG; metformin inhibits sugar metabolism
in vivo
We performed experiments in the NOD mouse, a well-established animal model of T1D. Prediabetic(4 weeks old) NOD mice were divided into four groups based on treatment with BCG injections and/or metformin (added to mouse chow) (n = 57 NOD mice). Specifically, the mice were treated with one dose of BCG
only, metformin only, both BCG and metformin, or no treatment (see STAR Methods for details) (Figure 6).
The results presented as Kaplan-Meier survival curves for the NOD mice show that BCG increases survival
compared with the untreated control group of mice or NOD mice treated with only metformin. In contrast,
the combination BCG and metformin accelerated death in these mice (Figure 6A). The BCG-only treatedmice had the highest survival rate, followed by the untreated controls and the metformin-treated mice. The
lowest survival rate was achieved in the group of NOD mice that were treated with both BCG and metformin, again suggesting that BCG and metformin treatments should not be combined. In the mouse, sufficient quantities of peripheral monocytes cannot be isolated, so instead we used freshly isolated bonemarrow cells from the NOD mice, in which we studied sugar transport by the 2-NBDG assay (Figure 6B).
As expected, BCG significantly increased the 2-NBDG uptake into freshly isolated bone marrow cells
from NOD mice (n = 11) as compared with untreated NOD mice (n = 16, p = 0.015) and also as comparedwith metformin-treated NOD mice where metformin inhibited the BCG-induced accelerated glycolysis(n = 15, p = 0.011).

Obese db/db mice, a model of T2D, respond to BCG with lowered sugars and reductions in
obesity
We also performed BCG experiments in the BKS db/db mice, a model of T2D. The mice were divided into 2
groups. One group was treated with multiple BCG injections, whereas the other group was untreated.
Changes in blood sugars and weight were monitored (Figures 6C and 6D). Blood sugars for the BCGtreated db/db (n = 16) were significantly lower than for the untreated db/db mice (n = 11). The corresponding weight reduction from their severe obesity is shown (Figure 6D). The open symbols depict time points
where the difference between CTRL and BCG groups was significant in student’s t testing. Because weightgain and hyperglycemia go hand-in-hand in db/db mice, the lower weight in the BCG-treated mice suggests better health and presumably better glycemic control. It should be noted that early db/db mouse
experiments tried one single dose of BCG; that dose failed to have a clinical outcome. Therefore, subsequent studies delivered four BCG doses.

10

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

Table 1. Diverse forms of diabetes: BCG responses in vivo and in vitro

HumansHumansHumansHumansMice

Mice

Diabetic

Diabetic

Diabetic

Controls

Diabetic

Diabetic

BCG in vivo

T1D

Ldada

T2D

Control

T1D (NOD)

T2D (db/db)

Age

AdultsAdultsAdultsNeonates

Adolescents

Adolescents

Route

ID

ID

Bladder

ID

ID

ID

StrainTokyo/Pasteur

Tokyo

TICE

Diverse

Tokyo

Tokyo

HbA1c

Y

None

NA

NA

Y

Y

Stimulated sugar

Augmented

ReducedNA

Augmented

Augmented

Augmented

BCG in vitro

T1D

LDADA

T2D

Control

T1D (NOD)

T2D (db/db)

Stimulated sugar

Large

Small

Normal r

NormalNA

NA

transport

response

response

esponseresponsetransport

We isolated bone marrow cells to test lymphoid sugar transport from all BCG-treated and untreated db/db
mice and performed 2-NBDG uptake experiments (Figure 6E). For both db/db and control mouse strains,the in vivo BCG treatments resulted in bone marrow cells that were capable of increased 2-NBDG uptake.
For the db/db mice, the results were significant at p = 0.04 (n = 10 for both untreated and BCG treatedgroups). For the BALC/c control mice that also were treated in vivo with BCG under the same conditions,the results trended higher for the BCG-treated group, but nonsignificantly so (p = 0.31; n = 4 for both untreated and BCG treated groups).

DISCUSSION
Microbe-host interactions have systemic effects on host metabolism. Both mycobacteria Mycobacterium
tuberculosis and Mycobacterium bovis as the BCG vaccine systemically influence sugar metabolism (Artset al., 2016; Cheng et al., 2014; Gleeson et al., 2016; Kühtreiber and Faustman, 2019; Kühtreiber et al.,2018, 2020; Shi et al., 2015). Here we began by comparing the effects of repeat BCG vaccinations in a pilot
clinical trial of adults with T1D and LADA. Using the Tokyo BCG strain, the two-year clinical trial demonstrated that subjects with T1D but not LADA had a statistically significant drop in HbA1c. This finding buttresses additional clinical trial data that now the Tokyo strain and Sanofi strain of BCG lowers HbA1c values
in T1D (Kühtreiber et al., 2018). In monocyte culture, T1D had the best and largest increase in stimulatedsugar transport after BCG exposure; LADA showed sluggish BCG-induced sugar transport, and this resulted in no clinical response. Despite the deficiency or compensation, sugar transport was stimulated
by 24-hour BCG exposure using the glucose uptake assay. We broadened our investigation to ask whether
other forms of diabetes, such as T2D, exhibited accelerated sugar uptake with this assay. We found monocytes from all forms of diabetes as well as NDCs responded to BCG in culture with accelerated sugar utilizations to varying degrees. Only in LADA was there an inherent minimal responsiveness. In mouse models,
the T2D mouse model was dependent on more doses of BCG, but then responded similar to the T1D
mouse model with lowered blood sugars. The universality of the effect implies that perhaps more formsof diabetes are likely to respond to BCG for therapeutic purposes by BCG augmented glycolysis, but
the dosing and the time frame could vary. The data for both in vivo and in vitro BCG sugar metabolism effects in human and mice are summarized (Table 1).
The longevity of the BCG vaccine’s systemic metabolic changes was evaluated by studying adults with decades-prior neonatal BCG vaccination. Remarkably, on average 55 years later, but extending up to 83 years,
newborn BCG vaccinations appear to yield a lymphoid system with accelerated glucose utilization similar
to those in more recently vaccinated human adults. The long-term durability of BCG effects on metabolism
and parallel data sets documenting BCG effects on metabolism affecting DNA methylation patterns inglycolysis pathways are consistent with observed stability of the effects over decades (Kühtreiber et al.,2020).
A topic of broad interest is whether BCG strains can make a difference in clinical outcomes, especially outcomes beyond tuberculosis protection (Anderson et al., 2012; Davids et al., 2006; Ponte et al., 2018). For

iScience 24, 103150, October 22, 2021

11

ll

OPEN ACCESS

this pilot human clinical trial, the Tokyo BCG strain was utilized. Our earlier T1D clinical trials used the Sanofi
BCG strain (Faustman et al., 2012; Kühtreiber et al., 2018). Both the Sanofi and Tokyo strains of BCG elicit
comparable metabolic and strong immune responses (Abdallah et al., 2015; Angelidou et al., 2020). Equivalence in vivo of BCG strains has not always been observed in relation to tuberculosis protection as well asprotection against off target infections (Shann, 2015). In bladder cancer comparison studies where highdose BCG is used, the Sanofi strain of BCG was superior to the TICE strain (Rentsch et al., 2014). In our current study, high-dose TICE for bladder cancer had no systemic effect on glucose metabolism, even whenthe exposures were six weekly high doses of BCG. In the case of T1D, the TICE strain used in new-onset T1D
in the past also failed to alter the diabetic disease course (Allen et al., 1999). In contrast, the Moreau andSanofi/Pasteur strain of BCG seemed to slow or prevent diabetes disease (Karaci, 2014; Parent et al., 1997).
A recent epidemiology study from BCG vaccination practices in Israel also supports the hypothesis that inhuman neonatal vaccinations with BCG, boosting doses has a protective impact on T1D, an effect observedwith the Moreau strain (Klein, 2020). Data from Turkey, using the Russia BCG strain, show that children
receiving three BCG vaccinations have statistically lower incidence of T1D than those receiving no or single
BCG vaccination (Karaci, 2014). Tuberculosis itself protects from both T1D and the onset of multiple sclerosis but is hardly a clinically relevant pathway for therapy (Airaghi and Tedeschi, 2006; Andersen et al.,1981). Lastly, a recent study in the elderly showed no protection from COVID-19 infections with the Danish
strain of BCG (Giamarellos-Bourboulis et al., 2020). These older Dutch citizens likely were also all vaccinated with BCG as newborns based on health practices, so the placebo group in this clinical trial likely
had lingering protection, making it difficult to see a difference in the recently revaccinated BCG citizens
to the previously vaccinated placebos. The data in this study show neonatal vaccinations as it relates tosugar transport continue to provide this high sugar uptake phenotype for decades as adults.
Will the BCG vaccine control blood sugars for T2D? The answer can only come from double-blinded clinical
trials. Still, the data reported here provides cause for optimism. After BCG culture, T2D lymphoid cells atbaseline were on average showing augmented sugar transport in a manner similar to monocytes from NDC
subjects. In T2D, there is no underlying defect that blocks this metabolic effect of BCG and, unlike LADA
subjects. The obese T2D mice did respond to BCG in vivo, but the dosing needed for this correction wasmuch higher. Fewer BCG doses were needed in the T1D NOD mouse models. After in vivo treatment, thelymphoid cells harvested from the both obese db/db and autoimmune NOD treated mice had accelerated
sugar transport. LADA human subjects who often have traits of T2D as well as T1D did not respond to BCG
vaccinations in vivo over a two-year time course; longer-term follow-up studies are underway. BCG vaccination in children protects American Indian populations from T2D, according to a study using early versionsof the Sanofi/Pasteur strain (Usher et al., 2019). Those American Indians were vaccinated as adolescents,
before the start of metformin therapy and before a diagnosis of T2D. This may be an important aspect
for achieving clinical trial success with BCG vaccinations in any form of diabetes; coadministration of
metformin blocks the innate and adaptive immune training. We observe this again with BCG culture experiments and in the NOD experiments. Two mouse models show BCG can lower plasma cholesterol levels
and delay atherosclerotic lesions in mice and eliminate the nonalcoholic fatty liver disease in obese diabetic ob/ob mice (Inafuku et al., 2015; Ovchinnikova et al., 2014; van Dam et al., 2016). Further follow-up
will be needed in the clinic to achieve clear answers for T2D diabetes with attention to BCG doses, thetime course of the responses, exclusion of metformin use at the time of dosing, time course for glycolysis
activity, the responses, and the BCG strain.
In therapeutic interventional trials in T1D and also autoimmune diseases such as multiple sclerosis, the BCG
effects, measured in terms of clinical outcome, all occur at about 2 years after the vaccinations. Recent evidence may help to explain the clinical observations that BCG as well as tuberculosis in humans (and mice)display such gradual clinical effects. Microbe BCG effects change both cytokines and glycolysis pathways. It
is now appreciated that these host systemic effects are due to the microbe changing gene expression
through methylation pattern rewiring. These processes take time and thus may explain the slow timecourse for the highly desirable and apparently permanent BCG effects on the immune system that may
involve the bone marrow stem cells (Cirovic et al., 2020; Das et al., 2013; Kaufmann et al., 2018; Mitroulis
et al., 2018). This BCG biologic journey may explain the delay in full clinical effects. These new discoveries
may also help to explain early data in infection protection where the mechanisms of BCG actions were
described as due to innate immunity, i.e., the use of monocytes and natural killer cells. If BCG does indeed
end up reprogramming stem cells, then the BCG effects on glucose uptake can be observed in T cell lineages and also in monocyte lineages. Our data on BCG vaccines in humans show T cells are reprogrammed

12

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

with BCG vaccinations, both in the setting of induction and modeling of the DNA by methylation changes
and glucose metabolic changes. Adaptive training may be delayed, and the consequence of bone marrow
retraining not just peripheral cytokine changes. Also, the 50+ year durability of prior BCG vaccinations
conferring continuing metabolic changes suggests the slow onset of the metabolism if offset by decades
long durability and perhaps an effect on stem cells.
Our pilot human clinical trial over a two-year time period does not address if LADA subjects will respondwith slower kinetics. Certainly a longer time for clinical observations and trial durations will be needed.
Monocytes from LADA monocytes in culture have very different metabolism of sugar compared with
T1D monocytes. T1D monocytes with and without BCG have a very augmented sugar transport index;
monocytes from LADA subjects are less responsive (Table 1). In many ways, these results are consistent
with the hygiene hypothesis (Strachan, 1989). This hypothesis is rooted in the observation that subjects
at most risk to allergies and autoimmunity have lessened microbe exposures. The fact that T1D is very
responsive to this form of microbial exposure might suggest low past exposures to microbes that with exposures in vitro or in vivo augment glycolysis. The fact that LADA patients’ onset of diabetes is delayed for20+ years might mean they have had some past microbe exposure that corrected the underlying glycolysis
defect, a delay in the disease onset. These data are consistent with the BCG vaccine prevention data wheremore BCG vaccines in childhood either outright prevent T1D or delay its onset (Karaci, 2014; Karaci and
Aydin, 2012). Because all subjects in this study have never had BCG vaccinations, the possible microbe
or other environmental factor providing this partial delay in disease onset is unknown.

Limitations of the study
The limitations of this study include the need to directly test multiple BCG vaccinations in the setting of T2D
with the correct BCG strain and to perform extended studies using LADA subjects to see if in vivo BCG
responsiveness in glucose metabolism can occur. Like any new application of a therapy, the success liesin the details of the BCG strain, the correct BCG dosing, and also the selection of subjects most responsive.
This study introduces the 2-NBDG assay as a monitoring tool for both human clinical trial data and also
NOD mouse treatment data. The metformin blocking experiments serve to validate the utility of the assay
and the need to carefully design clinical trials in T2D with an awareness of concurrent medications. The
assay may detect the most responsive diabetic populations and early therapeutic effectiveness. Lastly,
the ability of metformin to both block in vitro and in vivo BCG-induced glycolysis confirms the criticallink of mammalian target of rapamycin (mTOR) regulated metabolism for BCG effectiveness in lowering
blood sugars.

STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following:d KEY RESOURCES TABLE
d RESOURCE AVAILABILITY

B Lead contact
B Material availability
B Data and code availabilityd EXPERIMENTAL MODEL AND SUBJECT DETAILSB Human experimental design
B Animalsd METHOD DETAILSB Monocyte isolation and culture
B 2-NBDG sugar transport assay
d QUANTIFICATION AND STATISTICAL ANALYSIS

B Data analysis

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103150.

ACKNOWLEDGMENTS
This study was supported by The Iacocca Foundation. We thank Dr. Miriam Davis for editorial review.

iScience 24, 103150, October 22, 2021

13

iSciencell

ArticleOPEN ACCESSAUTHOR CONTRIBUTIONS
Conceptualization, Supervision, Data Analysis, and Manuscript writing: W.M.K. and D.L.F. Formal statisticalanalysis: H.Z. Recruitment of patients, conduct of human study visits, and human studies practices and protocols: N.N., K.J.N, and G.F.S. Conduct of 2-NBDG assays in humans: G.F.S. and A. A. Conduct of all mousestudies: H.T. and W.M.K. MW recruited T2D subjects.

DECLARATION OF INTERESTS
All authors declare no competing interests.

INCLUSION AND DIVERSITY
We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic orother types of diversity in the recruitment of human subjects. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design,
analysis, and/or interpretation of the work.

Received: March 5, 2021
Revised: June 3, 2021
Accepted: September 16, 2021
Published: October 22, 2021
REFERENCES
Aaby, P., Roth, A., Ravn, H., Napirna, B.M.,
Rodrigues, A., Lisse, I.M., Stensballe, L., Diness,
B.R., Lausch, K.R., Lund, N., et al. (2011).
Randomized trial of BCG vaccination at birth tolow-birth-weight children: beneficial nonspecificeffects in the neonatal period? J. Infect Dis. 204,
245–252. Published online 2011/06/16. https://doi.org/10.1093/infdis/jir240.

Anderson, E.J., Webb, E.L., Mawa, P.A., Kizza, M.,
Lyadda, N., Nampijja, M., and Elliott, A.M. (2012).
The influence of BCG vaccine strain on
mycobacteria-specific and non-specific immune
responses in a prospective cohort of infants in
Uganda. Vaccine 30, 2083–2089. Published online
2012/02/04. https://doi.org/10.1016/j.vaccine.
2012.01.053.

Aaby, P., Vessari, H., Nielsen, J., Maleta, K., Benn,
C.S., Jensen, H., and Ashorn, P. (2006). Sex
differential effects of routine immunizations andchildhood survival in rural Malawi. Pediatr. InfectDis. J. 25, 721–727. Published online 2006/07/29.
https://doi.org/10.1097/01.inf.0000227829.
64686.ae.

Angelidou, A., Conti, M.G., Diray-Arce, J., Benn,
C.S., Shann, F., Netea, M.G., Liu, M., Potluri, L.P.,
Sanchez-Schmitz, G., Husson, R., et al. (2020).
Licensed Bacille Calmette-Guerin (BCG)
formulations differ markedly in bacterial viability,
RNA content and innate immune activation.
Vaccine 38, 2229–2240. Published online 2020/02/
02. https://doi.org/10.1016/j.vaccine.2019.11.
060.

Abdallah, M., Hill-Cawthorne, G., Otto, T., et al.
(2015). Genomic expression catalogue of a global
collection of BCG vaccine strains show evidence
for highly diverged metabolic and cell-wall
adaptations. Sci. Rep. 5, 15443. https://doi.org/
10.1038/srep15443.
Airaghi, L., and Tedeschi, A. (2006). Negative
association between occurrence of type 1
diabetes and tuberculosis incidence at
population level. Acta Diabetol. 43, 43–45.
Published online 2006/07/26. https://doi.org/10.
1007/s00592-006-0210-x.
Allen, H.F., Klingensmith, G.J., Jensen, P.,
Simoes, E., Hayward, A., and Chase, H.P. (1999).
Effect of Bacillus Calmette-Guerin vaccination on
new-onset type 1 diabetes. A randomized clinicalstudy. Diabetes Care 22, 1703–1707. Published
online 1999/10/20. https://doi.org/10.2337/
diacare.22.10.1703.
Andersen, E., Isager, H., and Hyllested, K. (1981).
Risk factors in multiple sclerosis: tuberculin
reactivity, age at measles infection, tonsillectomy
and appendectomy. Acta Neurol. Scand. 63,
131–135. Published online 1981/02/01. https://doi.org/10.1111/j.1600-0404.1981.tb00756.x.

14

iScience 24, 103150, October 22, 2021

Arts, R.J.W., Carvalho, A., La Rocca, C., Palma, C.,
Rodrigues, F., Silvestre, R., Kleinnijenhuis, J.,
Lachmandas, E., Goncalves, L.G., Belinha, A.,et al. (2016). Immunometabolic pathways in BCGinduced trained immunity. Cell Rep 17, 2562–
2571. Published online 2016/12/08. https://doi.
org/10.1016/j.celrep.2016.11.011.
Arts, R.J.W., Moorlag, S., Novakovic, B., Li, Y.,
Wang, S.Y., Oosting, M., Kumar, V., Xavier, R.J.,
Wijmenga, C., Joosten, L.A.B., et al. (2018). BCG
vaccination protects against experimental viral
infection in humans through the induction ofcytokines associated with trained immunity. Cell
Host Microbe 23, 89–100.e105. Published online
2018/01/13. https://doi.org/10.1016/j.chom.
2017.12.010.
Babjuk, M., Bohle, A., Burger, M., Capoun, O.,
Cohen, D., Comperat, E.M., Hernandez, V.,
Kaasinen, E., Palou, J., Roupret, M., et al. (2017).
EAU guidelines on non-muscle-invasive urothelial
carcinoma of the bladder: update 2016. Eur. Urol.
71, 447–461. Published online 2016/06/22.
https://doi.org/10.1016/j.eururo.2016.05.041.
Biering-Sorensen, S., Jensen, K.J., Monterio, I.,
Ravn, H., Aaby, P., and Benn, C.S. (2018). Rapid

protective effects of early BCG on neonatal
mortality among low birth weight boys:
observations from randomized trials. J. Infect Dis.
217, 759–766. Published online 2017/12/08.
https://doi.org/10.1093/infdis/jix612.
Cheng, S.C., Quintin, J., Cramer, R.A.,
Shepardson, K.M., Saeed, S., Kumar, V.,
Giamarellos-Bourboulis, E.J., Martens, J.H., Rao,
N.A., Aghajanirefah, A., et al. (2014). mTOR- andHIF-1alpha-mediated aerobic glycolysis asmetabolic basis for trained immunity. Science
345, 1250684. Published online 2014/09/27.
https://doi.org/10.1126/science.1250684.
Cirovic, B., de Bree, L.C.J., Groh, L., Blok, B.A.,
Chan, J., van der Velden, W., Bremmers, M.E.J.,
van Crevel, R., Handler, K., Picelli, S., et al. (2020).
BCG vaccination in humans elicits trained
immunity via the hematopoietic progenitor
compartment. Cell Host Microbe 28, 322–334.
Published online 2020/06/17. https://doi.org/10.
1016/j.chom.2020.05.014.
Colditz, G.A., Brewer, T.F., Berkey, C.S., Wilson,
M.E., Burdick, E., Fineberg, H.V., and Mosteller, F.
(1994). Efficacy of BCG vaccine in the preventionof tuberculosis. Meta-analysis of the publishedliterature. JAMA 271, 698–702. Published online
1994/03/02.
Das, B., Kashino, S.S., Pulu, I., Kalita, D., Swami,
V., Yeger, H., Felsher, D.W., and Campos-Neto,A. (2013). CD271(+) bone marrow mesenchymal
stem cells may provide a niche for dormant
Mycobacterium tuberculosis. Sci. Transl Med. 5,170ra113. Published online 2013/02/01. https://doi.org/10.1126/scitranslmed.3004912.
Davids, V., Hanekom, W.A., Mansoor, N.,
Gamieldien, H., Gelderbloem, S.J., Hawkridge,
A., Hussey, G.D., Hughes, E.J., Soler, J., Murray,
R.A., et al. (2006). The effect of bacille CalmetteGuerin vaccine strain and route of administration
on induced immune responses in vaccinatedinfants. J. Infect Dis. 193, 531–536. PublishediSciencell

Articleonline 2006/01/21. https://doi.org/10.1086/
499825.
Davignon, L., Lemonde, P., St-Pierre, J., andFrappier, A. (1971). B.C.G. vaccination andleukaemia mortality. Lancet 1, 80–81. Published
online 1971/01/09. https://doi.org/10.1016/
s0140-6736(71)90804-x.
de Bree, L.C.J., Koeken, V., Joosten, L.A.B., Aaby,
P., Benn, C.S., van Crevel, R., and Netea, M.G.
(2018). Non-specific effects of vaccines: current
evidence and potential implications. Semin.
Immunol. 39, 35–43. Published online 2018/07/17.
https://doi.org/10.1016/j.smim.2018.06.002.
de Castro, M.J., Pardo-Seco, J., and MartinonTorres, F. (2015). Nonspecific (Heterologous)
protection of neonatal BCG vaccination against
hospitalization due to respiratory infection andsepsis. Clin. Infect Dis. 60, 1611–1619. Published
online 2015/03/01. https://doi.org/10.1093/cid/
civ144.
Faustman, D.L., Wang, L., Okubo, Y., Burger, D.,
Ban, L., Man, G., Zheng, H., Schoenfeld, D.,
Pompei, R., Avruch, J., et al. (2012). Proof-ofconcept, randomized, controlled clinical trial of
Bacillus-Calmette-Guerin for treatment of longterm type 1 diabetes. PLoS One 7, e41756.
Published online 2012/08/21. https://doi.org/10.
1371/journal.pone.0041756.
Freyne, B., Marchant, A., and Curtis, N. (2015).
BCG-associated heterologous immunity, ahistorical perspective: intervention studies inanimal models of infectious diseases. Trans. R.
Soc. Trop. Med. Hyg. 109, 52–61. Published
online 2015/01/13. https://doi.org/10.1093/
trstmh/tru197.
Giamarellos-Bourboulis, E.J., Tsilika, M.,
Moorlag, S., Antonakos, N., Kotsaki, A.,
Dominguez-Andres, J., Kyriazopoulou, E.,
Gkavogianni, T., Adami, M.E., Damoraki, G., et al.
(2020). Activate: randomized clinical trial of BCG
vaccination against infection in the elderly. Cell
183, 315–323.e319. Published online 2020/09/18.
https://doi.org/10.1016/j.cell.2020.08.051.
Gleeson, L.E., Sheedy, F.J., Palsson-McDermott,
E.M., Triglia, D., O’Leary, S.M., O’Sullivan, M.P.,
O’Neill, L.A., and Keane, J. (2016). Cutting edge:
mycobacterium tuberculosis induces aerobic
glycolysis in human alveolar macrophages that isrequired for control of intracellular bacillary
replication. J. Immunol. 196, 2444–2449.
Published online 2016/02/14. https://doi.org/10.
4049/jimmunol.1501612.
Goodridge, H.S., Ahmed, S.S., Curtis, N.,
Kollmann, T.R., Levy, O., Netea, M.G., Pollard,
A.J., van Crevel, R., and Wilson, C.B. (2016).
Harnessing the beneficial heterologous effects ofvaccination. Nat. Rev. Immunol. 16, 392–400.
Published online 2016/05/10. https://doi.org/10.
1038/nri.2016.43.
Higgins, J.P., Soares-Weiser, K., Lopez-Lopez,
J.A., Kakourou, A., Chaplin, K., Christensen, H.,
Martin, N.K., Sterne, J.A., and Reingold, A.L.
(2016). Association of BCG, DTP, and measles
containing vaccines with childhood mortality:
systematic review. BMJ 355, i5170. Published
online 2016/10/16. https://doi.org/10.1136/bmj.
i5170.
Hollm-Delgado, M.G., Stuart, E.A., and Black,
R.E. (2014). Acute lower respiratory infection

OPEN ACCESS

among Bacille Calmette-Guerin (BCG)vaccinated children. Pediatrics 133, e73–e81.
Published online 2014/01/01. https://doi.org/10.
1542/peds.2013-2218.

vaccinations upregulate myc, a central switch for
improved glucose metabolism in diabetes.
iScience 23, 101085. Published online 2020/05/08.
https://doi.org/10.1016/j.isci.2020.101085.

Inafuku, M., Matsuzaki, G., and Oku, H. (2015).
Intravenous Mycobacterium bovis Bacillus
Calmette-Guerin Ameliorates nonalcoholic fatty
liver disease in obese, diabetic ob/ob mice. PLoS
One 10, e0128676. Published online 2015/06/04.
https://doi.org/10.1371/journal.pone.0128676.

Kühtreiber, W.M., Tran, L., Kim, T., Dybala, M.,
Nguyen, B., Plager, S., Huang, D., Janes, S.,
Defusco, A., Baum, D., et al. (2018). Long-term
reduction in hyperglycemia in advanced type 1
diabetes: the value of induced aerobic glycolysis
with BCG vaccinations. NPJ Vaccin. 3, 23.
Published online 2018/06/29. https://doi.org/10.
1038/s41541-018-0062-8.

Kandasamy, R., Voysey, M., McQuaid, F., de Nie,K., Ryan, R., Orr, O., Uhlig, U., Sande, C.,
O’Connor, D., and Pollard, A.J. (2016). Nonspecific immunological effects of selected routine
childhood immunisations: systematic review.
BMJ 355, i5225. Published online 2016/10/16.
https://doi.org/10.1136/bmj.i5225.
Karaci, M. (2014). The protective effect of the BCG
vaccine on the development of type 1 diabetes inhumans. In The Value of BCG and TNF in
Autoimmunity, D. Faustman, ed. (Elsevier),
pp. 52–62.
Karaci, M., and Aydin, M. (2012). The effect of
BCG vaccine from protection of type 1 diabetes
mellitus. J. Contemp. Med 2, 1–8.
Katsarou, A., Gudbjornsdottir, S., Rawshani, A.,
Dabelea, D., Bonifacio, E., Anderson, B.J.,
Jacobsen, L.M., Schatz, D.A., and Lernmark, A.
(2017). Type 1 diabetes mellitus. Nat. Rev. Dis.
Primers 3, 17016. Published online 2017/03/31.
https://doi.org/10.1038/nrdp.2017.16.
Kaufmann, E., Sanz, J., Dunn, J.L., Khan, N.,
Mendonca, L.E., Pacis, A., Tzelepis, F., Pernet, E.,
Dumaine, A., Grenier, J.C., et al. (2018). BCG
educates hematopoietic stem cells to generate
protective innate immunity against. Tuberculosis.
Cell. 172, 176–190.e119. Published online 2018/01/13. https://doi.org/10.1016/j.cell.2017.12.031.
Kjaergaard, J., Birk, N.M., Nissen, T.N.,
Thostesen, L.M., Pihl, G.T., Benn, C.S., Jeppesen,
D.L., Pryds, O., Kofoed, P.E., Aaby, P., et al. (2016).
Nonspecific effect of BCG vaccination at birth on
early childhood infections: a randomized, clinicalmulticenter trial. Pediatr. Res. 80, 681–685.
Published online 2016/11/02. https://doi.org/10.
1038/pr.2016.142.
Klein, B.Y. (2020). Newborn BCG vaccination
complemented by boosting correlates betterwith reduced juvenile diabetes in females, thanvaccination alone. Vaccine 38, 6427–6434.
Published online 2020/08/11. https://doi.org/10.
1016/j.vaccine.2020.07.066.
Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten,
L.A., Jacobs, C., Xavier, R.J., van der Meer, J.W.,
van Crevel, R., and Netea, M.G. (2014). BCGinduced trained immunity in NK cells: role fornon-specific protection to infection. Clin.
Immunol. 155, 213–219. Published online 2014/12/03. https://doi.org/10.1016/j.clim.2014.10.
005.
Kühtreiber, W.M., and Faustman, D.L. (2019).
BCG therapy for type 1 diabetes: restoration ofbalanced immunity and metabolism. Trends
Endocrinol. Metab. 30, 80–92. Published online
2019/01/03. 10.1016/j.tem.2018.11.006.
Kühtreiber, W.M., Takahashi, H., Keefe, R.C.,
Song, Y., Tran, L., Luck, T.G., Shpilsky, G., Moore,
L., Sinton, S.M., Graham, J.C., et al. (2020). BCG

Mitroulis, I., Ruppova, K., Wang, B., Chen, L.S.,
Grzybek, M., Grinenko, T., Eugster, A., Troullinaki,
M., Palladini, A., Kourtzelis, I., et al. (2018).
Modulation of myelopoiesis progenitors is an
integral component of trained immunity. Cell 172,
147–161.e112. Published online 2018/01/13.
https://doi.org/10.1016/j.cell.2017.11.034.
Morales, A., Eidinger, D., and Bruce, A.W. (1976).
Intracavitary Bacillus Calmette-Guerin in thetreatment of superficial bladder tumors. J. Urol.
116, 180–183. Published online 1976/08/01.
https://doi.org/10.1016/s0022-5347(17)58737-6.
Odom, L.F., Morse, H., Tubergen, D.G., andBlake, M. (1988). Long-term survival of children
with acute non-lymphoblastic leukemia. Med.
Pediatr. Oncol. 16, 248–254. Published online
1988/01/01. https://doi.org/10.1002/mpo.
2950160405.
Ovchinnikova, O.A., Berge, N., Kang, C., Urien,C., Ketelhuth, D.F., Pottier, J., Drouet, L.,
Hansson, G.K., Marchal, G., Back, M., et al. (2014).
Mycobacterium bovis BCG killed by extended
freeze-drying induces an immunoregulatory
profile and protects against atherosclerosis. J.
Intern. Med. 275, 49–58. Published online 2013/08/22. https://doi.org/10.1111/joim.12127.
Parent, M.E., Siemiatycki, J., Menzies, R., Fritschi,
L., and Colle, E. (1997). Bacille Calmette-Guerin
vaccination and incidence of IDDM in Montreal,
Canada. Diabetes Care 20, 767–772. Published
online 1997/05/01. https://doi.org/10.2337/
diacare.20.5.767.
Pieralice, S., and Pozzilli, P. (2018). Latent
autoimmune diabetes in adults: a review onclinical implications and management. Diabetes
Metab. J. 42, 451–464. Published online 2018/12/
20. https://doi.org/10.4093/dmj.2018.0190.
Pollard, A.J., Finn, A., and Curtis, N. (2017). Nonspecific effects of vaccines: plausible andpotentially important, but implications uncertain.
Arch. Dis. Child 102, 1077–1081. Published online
2017/05/16. https://doi.org/10.1136/
archdischild-2015-310282.
Ponte, C., Hacker, M., Moraes, M., CastelloBranco, L., Silva, F., and Antas, P. (2018). The
patterns of in vitro cell-death and inflammatory
cytokines induced by distinct BCG vaccine strains
are differentially induced in human mononuclear
cells. Hum. Vaccin. Immunother. 14, 28–35.
Published online 2017/10/21. https://doi.org/10.
1080/21645515.2017.1382788.
Pozzilli, P., and Pieralice, S. (2018). Latent
autoimmune diabetes in adults: current status
and new horizons. Endocrinol. Metab. (Seoul) 33,
147–159. Published online 2018/06/28. https://doi.org/10.3803/EnM.2018.33.2.147.

iScience 24, 103150, October 22, 2021

15

iSciencell

ArticleOPEN ACCESS

Rentsch, C.A., Birkhauser, F.D., Biot, C., Gsponer,
J.R., Bisiaux, A., Wetterauer, C., Lagranderie, M.,
Marchal, G., Orgeur, M., Bouchier, C., et al.
(2014). Bacillus Calmette-Guerin strain
differences have an impact on clinical outcome inbladder cancer immunotherapy. Eur. Urol. 66,
677–688. Published online 2014/03/29. https://doi.org/10.1016/j.eururo.2014.02.061.
Ristori, G., Buzzi, M.G., Sabatini, U., Giugni, E.,
Bastianello, S., Viselli, F., Buttinelli, C., Ruggieri,
S., Colonnese, C., Pozzilli, C., et al. (1999). Use of
bacille Calmette-Guerin (BCG) in multiple
sclerosis. Neurology 53, 1588–1589.
Ristori, G., Romano, S., Cannoni, S., Visconti, A.,
Tinelli, E., Mendozzi, L., Cecconi, P., Lanzillo, R.,
Quarantelli, M., Buttinelli, C., et al. (2014). Effectsof Bacille Calmette-Guerin after the firstdemyelinating event in the CNS. Neurology 82,
41–48. Published online 2013/12/07. https://doi.
org/10.1212/01.wnl.0000438216.93319.ab.
Salmon, C., Conus, F., Parent, M.E., Benedetti, A.,
and Rousseau, M.C. (2019). Association between
Bacillus Calmette-Guerin vaccination andlymphoma: a population-based birth cohort
study. J. Intern. Med. 286, 583–595. Published
online 2019/07/31. https://doi.org/10.1111/joim.
12965.
Salmon, C., Conus, F., Parent, M.E., Benedetti, A.,
and Rousseau, M.C. (2020). Association between
Bacillus Calmette-Guerin (BCG) vaccination andlymphoma risk: a systematic review and metaanalysis. Cancer Epidemiol. 65, 101696.

16

iScience 24, 103150, October 22, 2021

Published online 2020/03/24. https://doi.org/10.
1016/j.canep.2020.101696.
Setia, M.S., Steinmaus, C., Ho, C.S., andRutherford, G.W. (2006). The role of BCG in
prevention of leprosy: a meta-analysis. Lancet
Infect Dis. 6, 162–170. Published online 2006/02/
28. https://doi.org/10.1016/S1473-3099(06)70412-1.
Shann, F. (2010). The non-specific effects ofvaccines. Arch. Dis. Child 95, 662–667. Published
online 2010/08/19. https://doi.org/10.1136/adc.
2009.157537.
Shann, F. (2015). Editorial commentary: different
strains of Bacillus Calmette-Guerin vaccine havevery different effects on tuberculosis and on
unrelated infections. Clin. Infect Dis. 61, 960–962.
Published online 2015/06/11. https://doi.org/10.
1093/cid/civ454.
Shi, L., Salamon, H., Eugenin, E.A., Pine, R.,
Cooper, A., and Gennaro, M.L. (2015). Infection
with mycobacterium tuberculosis induces the
Warburg effect in mouse lungs. Sci. Rep. 5, 18176.
Published online 2015/12/15. https://doi.org/10.
1038/srep18176.
Stanley, S.J., Howland, C., Stone, M.M., andSutherland, I. (1981). BCG vaccination of children
against leprosy in Uganda: final results. J. Hyg.
(Lond). 87, 233–248. Published online 1981/10/01.
https://doi.org/10.1017/s002217240006945x.
Stensballe, L.G., Nante, E., Jensen, I.P., Kofoed,
P.E., Poulsen, A., Jensen, H., Newport, M.,

Marchant, A., and Aaby, P. (2005). Acute lower
respiratory tract infections and respiratorysyncytial virus in infants in Guinea-Bissau: abeneficial effect of BCG vaccination for girls
community based case-control study. Vaccine 23,
1251–1257. Published online 2005/01/18. https://doi.org/10.1016/j.vaccine.2004.09.006.
Strachan, D.P. (1989). Hay fever, hygiene, andhousehold size. BMJ 299, 1259–1260. Published
online 1989/11/18. https://doi.org/10.1136/bmj.
299.6710.1259.
Usher, N.T., Chang, S., Howard, R.S., Martinez, A.,
Harrison, L.H., Santosham, M., and Aronson, N.E.
(2019). Association of BCG vaccination inchildhood with subsequent cancer diagnoses: a60-year follow-up of a clinical trial. JAMA Netw.
Open 2, e1912014. Published online 2019/09/26.
https://doi.org/10.1001/jamanetworkopen.2019.
12014.
van Dam, A.D., Bekkering, S., Crasborn, M., vanBeek, L., van den Berg, S.M., Vrieling, F., Joosten,
S.A., van Harmelen, V., de Winther, M.P.J.,
Lutjohann, D., et al. (2016). BCG lowers plasmacholesterol levels and delays atherosclerotic
lesion progression in mice. Atherosclerosis 251,
6–14. Published online 2016/05/28. https://doi.
org/10.1016/j.atherosclerosis.2016.05.031.
Yung, C.F. (2016). Non-specific effects ofchildhood vaccines. BMJ 355, i5434. Published
online 2016/10/16. https://doi.org/10.1136/bmj.
i5434.

iSciencell

ArticleOPEN ACCESS

STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCESOURCEIDENTIFIERBD Biosciences, Franklin Lakes, NJ

Cat# 555399

T1D, T2D and NDC volunteers

N/A

Japan BCG Laboratory, Tokyo, Japan

Lot# 1664-1

2-NBDG

ThermoFisher Scientific, Waltham, MA

Cat# N13195

BD FACSDiva CS&T Research Beads

BD Biosciences, Franklin Lakes, NJ

Cat#655051

CountBright Absolute Counting Beads

ThermoFisher Scientific, Waltham, MA

Cat# 2237596

Antibodies
APC anti-Human CD14 antibody
Biological samples
Human primary monocytes (isolated form whole blood)
Chemicals, peptides, and recombinant proteins
BCG
Critical commercial assays

Seahorse XF RPMI, pH7.4

Agilent Technologies, Santa Clara, CA

Cat# 00620006

FACScanto II

BD Biosciences, Franklin Lakes, NJ

Cat# 338960

NOD

The Jackson Laboratory, Bar Harbor, ME

Stock# 001976

db/db

The Jackson Laboratory, Bar Harbor, ME

Stock# 000697

Balb/cCharles River Laboratories, Wilmington, MA

Strain# 028

Experimental models: organisms/strains

Other
BD Vacutainer K2 EDTA Plus Blood Correction Tubes

BD Biosciences, Franklin Lakes, NJ

Cat# 365900

Goldenrod Animal Lancet 5mm

Fisher Scientific, Waltham, MA

Cat# NC9416572

ACCU-CHEK Aviva Plus

Roche, Basel, Switzerland

Cat# 06988580001

ACCU-CHEK Aviva Plus 50 Test Strips

Roche, Basel, Switzerland

Cat# 06908349001

Mod LabDietR 5P00 with 0.1% Metformin

TestDiet, Richmond, IN

Cat# 1818831-214

BD 1mL Syringe

BD Biosciences, Franklin Lakes, NJ

Cat# 309628

PrecisionGlide Needle 30G1/2

BD Biosciences, Franklin Lakes, NJ

Cat# 305106

EasySep Direct Human Monocyte Isolation Kit

Stemcell Technologies, Cambridge, MA

Cat# 19669

TM

Stemcell Technologies, Cambridge, MA

Cat# 10961

Nunc UpCell 24 Multidish

ThermoFisher Scientific, Waltham, MA

Cat# NU24W1813

PBS, pH7.4

ThermoFisher Scientific, Waltham, MA

Cat# 20012-027

Easy 50 Magnet

ThermoFisher Scientific, Waltham, MA

Cat# 18001

EDTA

Sigma Aldrich, St. Louis, MO

Cat# E-7889

Immunocult-SF Macrophage Medium

Penicillin-Streptomycin

ThermoFisher Scientific, Waltham, MA

Cat# 15140122

RBC Lysis buffer

ThermoFisher Scientific, Waltham, MA

Cat# 00-4333-57

RPMI

ThermoFisher Scientific, Waltham, MA

Cat# 61870036

Falcon Cell Strainers (40mm)

Corning, Glendale, AZ

Cat# 352340

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by
the lead contact, Denise. L. Faustman (faustman@helix.mgh.harvard.edu).

Material availability
This study did not generate new unique reagents.

iScience 24, 103150, October 22, 2021

17

ll

OPEN ACCESS

Data and code availability
All data reported in this paper and any additional information will be shared by the lead contact uponrequest. This paper does not report original code. Additional resource: The clinical registry number is
NCT02081326 (https://clinicaltrials.gov/ct2/show/NCT02081326).

EXPERIMENTAL MODEL AND SUBJECT DETAILSHuman experimental design
We undertook a single-center open-label pilot clinical trial conducted at the Massachusetts General Hospital (Boston, MA, USA). All human studies had full institutional approvals through Massachusetts General
Hospital and Partners Health Care. The BCG interventional studies were also formally approved by the FDA(IND#2013P16434). The open-label patients were given two intradermal BCG vaccinations (Tokyo 172 BCG,
Japan BCG Laboratory, Tokyo, Japan) at baseline and a second vaccine four weeks later. All blood donors,
both T1D, T2D and non-diabetic control subjects, consented through Study #2001P001379. Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human Services Belmont Report. The timing of
the serial blood sampling times for the pilot clinical trial was screening (pre-BCG vaccine), 6 months, year
01, year 1.5 and year 02.
All subjects, for inclusion into this pilot trial, had to be free at enrollment of significant diabetic complications such as retinopathy, amputations, cardiac disease, neuropathy as well as having no other co-morbidities, such as cancer, etc.
The pilot clinical trial reported here enrolled 16 diabetics; 6 of these diabetics (%Female of 0) had an early
age of onset with a mean age of 11 G 3 (duration of 18 G 3 years; current age 28 G 3). Ten of these diabetic
subjects (%Female of 60) had a late age of onset with the mean age of onset of 31 G 2 (duration of 19 G 2years; current age of 45 G 4 years). A reference population of type 1 diabetic subjects, were also simultaneously followed (n = 40; %Female of 47.5) with an age of onset of 26 G 2 (duration 13 G 2 age of onset;
current age of 40 G 2 years). This data was compared to our earlier data on early age of onset subjects in the
our Phase I clinical trial, dosed with the Sanofi strain of BCG, mean age of onset 11.3 G 5.8 (current age
36.0 G 2.1; duration of 24.7 G 5.8 years) (Kühtreiber et al., 2018). For clarity throughout this paper wewill refer to the two populations of diabetic subjects participating in the pilot as juvenile-onset T1D(AOO% 21 years) or adult-onset T1D subjects as Latent Autoimmune Diabetes in Adults (LADA) with
AOO >21 years (Pozzilli and Pieralice, 2018). Percentage of female cohorts are 0 and 40.0 in juvenile-onset
and LADA, respectively, therefore while no significant influence of sex is considered in LADA comparison(p = 0.7, Chi-square test), male-skewed cohorts could affect the results in juvenile onset T1D (p = 0.02).
The stimulated glucose index in T1D (n = 24), LADA (n = 12) and NDC (n = 16)-derived monocytes were alsomeasured. Percentage of Female cohorts was 54.5, 31.6 and 50, respectively. Unfortunately, sex information of 3 T1D and one LADA cohorts were missing. Chi-square test were performed to see sex-related
bias in these comparisons, finding that no significant difference at each comparison (NDC vs T1D,
p = 0.3; NDC vs LADA, p = 0.7; T1D vs LADA, p = 0.2).
In this paper we also study type 2 diabetic (T2D) subjects with their typical traits of obesity, adult onset of
diabetic disease and receipt of many forms of oral hypoglycemia agents as well as insulin therapy. This population had an average age of onset of 54.7 G 3.0 years, disease duration of 15.2 G 1.6 years, and current
age of 70.1 G 2.6; n = 13 subjects (%Female of 53.8). These were compared with NDC (n = 21; current age of
57.1 G 4.2 years; %Female of 57.1) and/or T1D (n = 42, current age of 37.3 G 2.8 years; age of onset of
20.0 G 2.3 years; disease duration of 17.6 G 2.1 years; %Female of 35.9) subjects in 2NBDG assay (Table
S1). No significant difference in gender bias was found within individual comparisons (NDC vs T1D,
p = 0.1; NDC vs T2D, p = 0.8; T1D vs T2D, p = 0.2, chi-square test), indicating no influence of sex on theassay. In addition, 13 of 21 NDC subject were neonatal BCG-vaccinated (%Female of 46.1), which also
excluded sex-related bias in the comparison between them (p = 0.2).
We also studied 3 patients that received BCG treatment for bladder cancer (%Female of 0, p = 0.04). Thus,
this result has a possibility of sex-linked influence. One of these patients was treated twice because ofrecurrent disease. The bladder cancer patients had an average BCG dosing age of 67.8 G 2.6 years andan average age of 74.0 G 2.4 years at the time of blood draw.

18

iScience 24, 103150, October 22, 2021

iScience
ArticleiSciencell

ArticleOPEN ACCESS

Blood from BCG-treated diabetic and non-diabetic control subjects (NDC) was collected in purple top
tubes (BD Vacutainer, K2EDTA anti-coagulant) (Becton, Dickinson and Company; Franklin Lakes, NJ,
USA). Sample HbA1c levels were processed directly from fresh blood by certified diagnostic laboratories
approved by Massachusetts General Hospital.

Animals
Five-week-old BALB/c male, NOD female, and db/db male mice (The Jackson Laboratory, Bar Harbor, ME,USA) were housed under specific pathogen-free conditions. The mice were carefully monitored daily freely
fed on normal diet and were not fasted before a challenge or assessment. When the mice showed signs ofcachexia such as prominent loss of body weight or became moribund, they were immediately euthanized.
The care of mice and experimental procedures were complied with the ‘‘Principles of Laboratory Animal
Care’’ (Guide for the Care and Use of Laboratory Animals, National Institutes of Health publication 8623, 1985). The experimental protocol was approved by the Institutional Animal Care and Use Committeeof Massachusetts General Hospital (Approval protocol# 2017N000137).
The mice were housed in five animals per cage at the MGH animal facilities (four animals per cage after theyreached a weight of >25 grams). Body weight and blood sugar measurements were taken weekly tomonitor diabetes progression. Blood was obtained from tail nicks using a 5.5 mm animal lancet(MEDIpoint; Mineola, NY) and glucose was measured using an Aviva Plus glucometer (Accuchek; Indianapolis, Indiana). BCG was injected by footpad at a dose of 25 mL of BCG (2mg/ml in saline; Japan BCG
Laboratory; Tokyo, Japan). Treated and untreated mice were sacrificed using CO2 and bone marrow was
isolated from femurs and purified with RBC Lysis buffer (Thermofisher Scientific, Waltham, MA). One million
cells were resuspended in 50mL Agilent Seahorse XFp media and mixed with 50 mL of 2-NBDG (0.2 mM in
XFp, (Agilent, Santa Clara, CA, USA) . The suspension was incubated in a CO2-free incubator at 37 C for
30 minutes, washed and resuspended in 300 mL XFP. The cells were analyzed on a FacsCanto II flow cytometer. Data was analyzed using FlowJo software.
NOD mice (Jackson Labs; Bar Harbor, ME) were used as a model for T1D. A subgroup of NOD mice werestarted on metformin (0.1%) mixed into mouse chow (Scott Pharma Solutions; Marlborough, MA) at 6 weeks
of age. After one month, half of the mice in the metformin group, and half of the mice in the control groupwere injected a single time with BCG. NOD mice were euthanized at 16–18 weeks of age and their bonemarrow cells were harvested for 2NBDG assay. BALB/c and BKS db/db mice (Jackson Labs; Bar Harbor,ME) were used as models for non-diabetic control and T2D, respectively. Early experiments with the db/
db mouse revealed a single injection of BCG at 7 weeks of age was insufficient to change blood sugar
or weight, four BCG injections in alternating rear footpads were administered when the mice were 8, 14,
20 and 23 weeks old (data shown). Also, these mice were euthanized at 26–28 weeks of age.

METHOD DETAILS
Monocyte isolation and culture
Whole blood samples were collected from human participants and monocytes were isolated using the
StemCell Technologies Direct Human Monocyte Isolation kit (Stemcell Technologies, Vancouver, BC,
Canada) and cultured overnight at 37 C and 5% CO2. The culture media was Immunocult media (Stemcell
Technologies) the cells were placed into 24-well Nunc UpCell culture plates (Thermofisher Scientific, Waltham, MA) at 1 3 106 monocytes per well. Culture conditions included with or without BCG (1 3 106 CFU/
well, BCG Japan, Tokyo, Japan) and with or without metformin (1 mM, Sigma Aldrich, St. Louis, MO). UpCell
plates have temperature-responsive surfaces that allow cells to attach at 37 C, but release the cells at room
temperature or below. To harvest the cells, the warm culture media was replaced with 1 mL of cold XFP
buffer (Agilent Technologies, Santa Clara, CA) and the plates left at room temperature for 20 min to allow
the cells to detach. The cells were then harvested and transferred to Eppendorf tubes.

2-NBDG sugar transport assay
Harvested monocytes were washed with XFP buffer, counted, resuspended at 250K monocytes in 50 mL of
XFP, mixed with 50 mL 2-NBDG in XFP (ThermoFisher, end concentration 0.1 mM) and incubated at 37 C for
20 min in a CO2-free incubator. Five mL of APC anti-human CD14 antibody (Company, City, State) was thenadded and incubated at 37 C for an additional 10 min. Unstained autofluorescence control samples wereincubated without 2-NBDG and without CD14 antibody. Following incubation, the cells were washed with

iScience 24, 103150, October 22, 2021

19

ll

OPEN ACCESSXFP buffer, resuspended in 300uL of XFP buffer and analyzed on a FacsCanto II flow cytometer (BD Biosciences, San Jose, CA). Data was analyzed using FlowJo software (FlowJo LLC, Ashland, OR; division of
Becton, Dickinson & Company) by quantifying 2-NBDG fluorescence intensity (MFI).
Human primary monocytes were isolated using EasySep Direct Human Monocyte Isolation Kit (Stemcell
Technologies, Cambridge, MA) following the manufacturer’s protocol. Briefly, 1000 mL of Isolation Cocktail
and 1000 mL of RapidSpheres were mixed with 20 mL of whole blood in a 50 mL centrifuge tube andincubated for 5 min at room temperature. Thirty milliliter of PBS containing 1mM EDTA (Sigma Aldrich,
St. Louis, MO) was added and the tube placed into an ‘‘Easy 50’’ magnet. After 10 min, the monocytes-enriched suspension was transferred into a new tube, and then the magnetic separation process was
repeated for 5 min with fresh, same amount RapidSpheres. The resulting highly monocytes-enriched suspension was transferred into another new tube and purified for a third time using the magnet.
The isolated 1 3 106 human monocytes were cultured in 1mL ImmunocultTM-SF Macrophage Medium(Stemcell Technologies) supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin (ThermoFisher
Scientific). Half of the wells were incubated with 1 3 105 CFU of BCG (JAPAN BCG Laboratory, Tokyo,
JAPAN) and the others with normal culture medium for control at 37 C in 5% CO2 and 95% air. The
following day, the cells were harvested and analyzed by 2-NBDG assay.

QUANTIFICATION AND STATISTICAL ANALYSIS
Data analysis
Statistical significance in the 2-NBDG experiments was determined by Student’s t test to compare twogroups. p values less than 0.05 were considered statistically significant. Pairing and number of tails usedin the t tests are listed in the legend of the figures. Statistics were performed in Excel or GraphPad PRISM
version 9. Levels of significance are shown in the figures using the following key: p < 0.05 *; p < 0.01 **;p < 0.001 ***, p < 0.0001****.

20

iScience 24, 103150, October 22, 2021

iScience
Article